semaglutide fda approval date approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease semaglutide fda approval date semaglutide

We understand you might be feeling cautious about what seems to be a simple solution

Founded in 2021, the platform has rapidly scaled while maintaining the kind of quality markers published clinical research, CoA testing, lab work, and dietitian access that define best-in-class GLP-1 care

The best choice depends on your individual situation, health conditions, and goals

For example, a 72-week phase II trial involving 320 patients with MASH, reported MASH resolution rates of up to 59% at the highest dose of 0.4 mg daily as compared to 17% in the placebo group

This means your body receives less of the active compound than intended, potentially reducing the appetite-suppressing effects you depend on

Additionally, the option of taking Wegovy without injections may align better with busy or travel-heavy schedules